Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Q2 Net Loss Falls Amid Lower R&D Costs

Premium

Alnylam Pharmaceuticals this week reported a lower second-quarter net loss amid a sharp decrease in research and development spending.

The company's loss for the quarter dipped to $14.6 million, or $0.35 a share, from $22.7 million, or $0.12 per share, the year before. Alnylam attributed the decrease to a $11 million payment made to partner Isis Pharmaceuticals last year related to an agreement over single-stranded RNAi technology (GSN 4/30/2009).

Alnylam's revenues in the second quarter rose slightly to $26.6 million from $24.6 million the year before, and included $14 million in collaborative revenue from Roche, $5.6 million related to its alliance with Takeda Pharmaceuticals, and $1.9 million in license fees from Regulus Therapeutics, Alnylam's microRNA drugs joint venture with Isis.

Research and development spending in the quarter fell to $28.1 million from $38.6 million the prior year, again partially related to the ssRNAi payment to Isis. Meanwhile, general and administrative costs edged up to $10.1 million from $8.4 million.

As of June 30, Alnylam had cash, cash equivalents, and marketable securities totaling $396.9 million. The company said it expects to end 2010 with greater than $325 million.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.